Bottom Line:
The US FDA expanded its approval of the RSV (respiratory syncytial virus) vaccine AREXVY to individuals 50-59 years old with an increased risk of severe disease with RSV. This new approval should make accessing the vaccine easier for all those 50 and older with CLL / SLL to protect against RSV infection, a potentially serious pulmonary illness. The FDA granted this approval on Sunday, June 7, 2024.
Details and Background:
Until this expanded approval, the two available RSV vaccines were only FDA-approved for those 60 years and older.
This new indication for only one of the two approved vaccines, GSK’s AREXVY, is for those at increased risk of severe outcomes from an RSV infection between ages 50 and 59. Examples of high risk given are chronic obstructive pulmonary disease (COPD), asthma, heart failure, and diabetes. However, anyone with impaired immunity, such as those with chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL), should also qualify.
RSV is a viral infection that can cause life-threatening lower respiratory infections in adults and children. It is particularly dangerous for those who already have respiratory problems or other illnesses that increase the risk of severe disease.
There is an ongoing trial for its use in immunocompromised adults older than 18. Until that study concludes, this approval should make it easier for those over 50 with CLL / SLL to access the vaccine.
It is recommended that you have a detailed discussion with your healthcare provider about the risks and benefits of the RSV vaccine. This will help you make an informed decision about whether the vaccine is suitable for you.
Read the official press release: US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
